A Trial of SHR-1701 in Subjects With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2020

Primary Completion Date

February 1, 2023

Study Completion Date

February 1, 2023

Conditions

Advanced Solid Tumor

Interventions

DRUG

SHR-1701

Anti-PD-L1/TGFβ fusion protein

Trial Locations (4)

Icon Cancer Care Centre, South Brisbane

Scientia Clinical research, Sydney

Sydney South West Private, Sydney

Linear Clinical Research, Perth

All Listed Sponsors

lead

Atridia Pty Ltd.

INDUSTRY

NCT04324814 - A Trial of SHR-1701 in Subjects With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter